Home › Funds › United Super Pty Ltd in its capacity as Trustee for the Cons › ABT

United Super Pty Ltd in its capacity as Trustee for the Cons position in ABT

ABBOTT LABORATORIES · Health Care

United Super Pty Ltd in its capacity as Trustee for the Cons reported holding 690,864 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$68.3M, representing 0.90% of its reported portfolio and ranking #22 among its reported holdings. United Super Pty Ltd in its capacity as Trustee for the Cons has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)690.86K sh
Reported value held$68.28M
Portfolio Weight0.90%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How United Super Pty Ltd in its capacity as Trustee for the Cons's ABT position evolved

United Super Pty Ltd in its capacity as Trustee for the Cons first disclosed a stake in ABT in Q3 2023 at 634,251 shares (US$61.4M). The position peaked in Q3 2024 at 717,259 shares, worth US$81.8M. Across 13 filings, United Super Pty Ltd in its capacity as Trustee for the Cons increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 690,864 shares valued at US$68.3M — an increase of 25,200 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 634.25K $61.43M New
Q4 2023 695.64K $76.57M Add
Q1 2024 717.26K $81.52M Add
Q2 2024 717.26K $74.53M Hold
Q3 2024 717.26K $81.77M Hold
Q4 2024 632.43K $71.53M Reduce
Q1 2025 567.92K $75.33M Reduce
Q2 2025 544.81K $74.10M Reduce
Q3 2025 544.81K $72.97M Hold
Q4 2025 544.81K $68.26M Hold
Q1 2026 665.66K $68.34M Add
Q2 2026 665.66K $60.40M Hold
Q3 2026 690.86K $68.28M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has United Super Pty Ltd in its capacity as Trustee for the Cons held ABT?

United Super Pty Ltd in its capacity as Trustee for the Cons has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is United Super Pty Ltd in its capacity as Trustee for the Cons's current position in ABT?

As of Q3 2026, United Super Pty Ltd in its capacity as Trustee for the Cons holds 690.86K shares of ABT (ABBOTT LABORATORIES), valued at $68.28M, representing 0.90% of its reported portfolio and ranking #22.

Has United Super Pty Ltd in its capacity as Trustee for the Cons been buying or selling ABT?

In the latest 13F filing (Q3 2026), United Super Pty Ltd in its capacity as Trustee for the Cons increased its position in ABT. The position peaked in Q3 2024 at 717.26K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.